stockrowMesoblast Limited (MESO) vs Nurix Therapeutics, Inc. (NRIX)
- Mesoblast Limited MESO 13.21 +0.84%
- Nurix Therapeutics, Inc. NRIX 15.51 −0.58%
Mesoblast Limited and Nurix Therapeutics, Inc. are both Biotechnology companies. Mesoblast Limited and Nurix Therapeutics, Inc. are of similar size ($1.7B and $1.7B). Mesoblast Limited has negative trailing earnings, so its P/E is not meaningful; Nurix Therapeutics, Inc. trades at 6.2×. Nurix Therapeutics, Inc. grew revenue faster over the last twelve months: 738.8% against −26.5%. Nurix Therapeutics, Inc. has the higher net margin (42.0% vs −1,091.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Nurix Therapeutics, Inc. leads on 14 and Mesoblast Limited on 3.
Valuation
Profitability
| Metric | MESO | NRIX | Biotechnology median |
|---|---|---|---|
| Gross margin | (269.72%) | 100.00% | 67.24% |
| Operating margin | (826.28%) | 41.27% | 0.00% |
| Net margin | (1,091.71%) | 42.01% | 0.00% |
| Free cash flow margin | 0.00% | 52.68% | 0.00% |
| Return on equity | 0.00% | 43.99% | (50.28%) |
| Return on assets | 0.00% | 34.33% | (45.89%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack